呼吸道合胞病毒及其疫苗研究进展  

Research and development of respiratory syncytial virus and its vaccines

作　　者：张泰然 王汀[1] ZHANG Tairan;WANG Ting(School of Pharmacy,Anhui Medical University,Hefei 230032,China)

机构地区：[1]安徽医科大学药学院,安徽合肥230032

出　　处：《中国药剂学杂志(网络版)》2025年第1期36-43,共8页Chinese Journal of Pharmaceutics:Online Edition

摘　　要：目的介绍呼吸道合胞病毒(respiratory syncytial virus,RSV)及其疫苗的最新研究现状。方法通过查阅相关文献,总结并阐述呼吸道合胞病毒的感染性及其各类疫苗的研究状况。结果目前已经发展了减毒活疫苗、病毒载体疫苗、重组蛋白疫苗、核酸疫苗等不同类型,其中Arexvy和Abrysvo亚单位疫苗已经在美国批准上市。结论呼吸道合胞病毒疫苗研究已经取得了突破性的进展,已经有产品进入市场,为应对RSV对人类健康造成的威胁提供了有力手段。Objective To introduce the latest advancements of research on the respiratory syncytial virus(RSV)and its vaccines.Method The characteristics of RSV and the research status of various vaccines against RSV were summarized by searching the relevant literatures.Results Through continuous in-depth research on respiratory syncytial virus,significant breakthroughs have been made in developing various vaccines,such as live attenuated vaccines,viral vector vaccines,recombinant protein subunit vaccines,and nucleic acid vaccines.Among these,Arexvy®and Abrysvo®,the two subunit vaccines have been approved for marketing in the United States.Conclusion Great achievements made in the research on RSV and its vaccines have pushed two subunit vaccines into markets as a powerful tool against RSV and its infection threat to human health.

关 键 词：呼吸道合胞病毒 减毒活疫苗 病毒载体疫苗 重组蛋白疫苗 核酸疫苗 

分 类 号：R392[医药卫生—免疫学]